ASPIRIN/REYE'S SYNDROME LABEL WARNING LEGISLATION IN ILLINOIS
ASPIRIN/REYE'S SYNDROME LABEL WARNING LEGISLATION IN ILLINOIS is now pending action by a Senate cmte. of the state legislature. Introduced March 27 by Sen. Jeremiah Joyce, the bill would amend the Illinois FD&C Act to prohibit the offering for sale of "any aspirin the label of which does not warn against giving aspirin to any person under 18 years of age recently suffering from chicken pox to the danger of contracting Reye's Syndrome." The bill is being considered by the Illinois Senate's Public Health Cmte. The bill is the first attempt by a state to require a label warning of an association between Reye's Syndrome and aspirin. The agency began developing a proposal on an aspirin label warning rule in June 1982 at the request of former HHS Secty. Schweiker. The proposal was subsequently stayed by Schweiker in November 1982 in the face of opposition by the American Academy of Pediatrics, which said a warning should be delayed pending more conclusive evidence, and the Office of Management & Budget. In lieu of a label warning, FDA initiated public service advertisements to inform the public of a possible link between salicylates and Reye's Syndrome. The Illinois initiative is similar to action taken by California on the issue of an OTC pregnancy/nursing warning. California's law requiring a label warning for systemic OTCs forced FDA to propose a uniform warning to avoid conflicting state-by-state label requirements. The regulation was subsequently adopted by FDA. The Illinois bill if passed could raise the issue of federal preemption again.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth